NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 - NMD Pharma A/S, a clinical-sta ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.-    ASC30 SQ depo ...

Peptilogics' PLG0206 is a first-in-class anti-biofilm drug candidate being studied in patients with prosthetic joint infection (PJI), the first of multiple potential medical device-related infections ...

The National Institute of Open Schooling is finalising the NIOS Date Sheet 2026 for the April-May theory examinations. The detailed schedule for Secondary and Senior Secondary courses is expected on ...

Ecopipam is a first-in-class investigational small-molecule therapy that selectively blocks dopamine-1 (D1) receptors. It is not an antipsychotic. This mechanism differs from currently approved ...

And yet for all the billions of dollars spent, for all the prescriptions written, a fundamental question has lingered like a low hum beneath the clinical noise: where, precisely, does GLP-1 live ...

NYC is planning upgrades to enhance the 14th Street busway with improvements for pedestrians, cyclists, and transit riders ...

The numbers don’t make for pretty reading. Between 2011 and 2021, the number of students studying English literature at ...

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

What happens when you focus on the things that truly matter and strip away the things that don’t?” the president said.

The Chinese Communist Party has embraced the study of Greek and Latin—as, in some ways, an antidote to the modern West.